Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
BTIG finds medical technology stocks with exposure with SVB » 13:10
03/12/23
03/12
13:10
03/12/23
13:10
IRTC

iRhythm

$107.28 /

-8.07 (-7.00%)

, SIVB

SVB Financial

$105.92 /

-0.04 (-0.04%)

, ATRC

AtriCure

$35.90 /

-1.72 (-4.57%)

, VRAY

ViewRay

$3.62 /

-0.265 (-6.82%)

, TMCI

Treace Medical

$24.07 /

-0.66 (-2.67%)

, VCEL

Vericel

$29.42 /

-0.29 (-0.98%)

, ORGO

Organogenesis

$2.28 /

-0.035 (-1.52%)

, HUMA

Humacyte

$2.72 /

-0.11 (-3.89%)

, LNSR

Lensar

$3.21 /

+0.02 (+0.63%)

BTIG analysts compiled a…

BTIG analysts compiled a list of companies in its coverage that may have potential exposure to SVB Financial (SIVB), either through loan agreements, revolving credit facilities, and/or transactions. The list includes iRhythm Technologies (IRTC), AtriCure (ATRC), ViewRay (VRAY), Treace Medical (TMCI), Vericel (VCEL), Organogenesis (ORGO), Humacyte (HUMA) and Lensar (LNSR). The firm is not changing its estimates or ratings at this time.

ShowHide Related Items >><<
VRAY ViewRay
$3.62 /

-0.265 (-6.82%)

VCEL Vericel
$29.42 /

-0.29 (-0.98%)

TMCI Treace Medical
$24.07 /

-0.66 (-2.67%)

SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

ORGO Organogenesis
$2.28 /

-0.035 (-1.52%)

IRTC iRhythm
$107.28 /

-8.07 (-7.00%)

HUMA Humacyte
$2.72 /

-0.11 (-3.89%)

ATRC AtriCure
$35.90 /

-1.72 (-4.57%)

IRTC iRhythm
$107.28 /

-8.07 (-7.00%)

02/24/23 Canaccord
iRhythm price target raised to $143 from $135 at Canaccord
02/07/23 Wells Fargo
iRhythm initiated with an Overweight at Wells Fargo
12/12/22 Citi
iRhythm price target lowered to $110 from $144 at Citi
11/07/22 Wolfe Research
iRhythm upgraded to Peer Perform from Underperform at Wolfe Research
SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

03/12/23 Barclays
Barclays reveals software names that could be impacted by SVB
03/10/23 Maxim
SVB Financial downgraded to Sell from Buy at Maxim
03/10/23 Baird
West Coast REITs underperforming on SVB news, says Baird
03/10/23 Stifel
Stifel says SVB fallout 'appears limited' across firm's biotech coverage
ATRC AtriCure
$35.90 /

-1.72 (-4.57%)

02/22/23 BTIG
AtriCure price target lowered to $55 from $65 at BTIG
02/22/23 Stifel
AtriCure price target lowered to $48 from $55 at Stifel
02/22/23 Canaccord
AtriCure price target lowered to $74 from $81 at Canaccord
02/06/23 Canaccord
AtriCure price target raised to $81 from $67 at Canaccord
VRAY ViewRay
$3.62 /

-0.265 (-6.82%)

01/05/23 Piper Sandler
Piper Sandler bullish on ViewRay following two large MRIdian agreements
11/17/22 B. Riley
ViewRay resumed with a Buy at B. Riley
11/02/22 Piper Sandler
ViewRay price target raised to $6.50 from $6 at Piper Sandler
10/23/22 Piper Sandler
Abstracts show superior outcomes provided by MRIdian, says Piper Sandler
TMCI Treace Medical
$24.07 /

-0.66 (-2.67%)

09/21/22 BTIG
Treace Medical price target raised to $28 from $23 at BTIG
09/21/22 Stifel
Treace Medical price target raised to $27 from $24 at Stifel
07/18/22 Stifel
Treace Medical price target lowered to $21 from $32 at Stifel
05/12/22 BTIG
Treace Medical initiated with a Buy at BTIG
VCEL Vericel
$29.42 /

-0.29 (-0.98%)

01/31/23 Truist
Vericel price target raised to $29 from $25 at Truist
01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
ORGO Organogenesis
$2.28 /

-0.035 (-1.52%)

11/10/22 BTIG
Organogenesis downgraded to Neutral from Buy at BTIG
08/10/22 Oppenheimer
Oppenheimer downgrades Organogenesis to Perform on lowered guidance
08/10/22 Oppenheimer
Organogenesis downgraded to Perform from Outperform at Oppenheimer
HUMA Humacyte
$2.72 /

-0.11 (-3.89%)

12/19/22 TD Cowen
Humacyte price target lowered to $5 from $8 at Cowen
11/10/22 Piper Sandler
Humacyte price target lowered to $2.75 from $3.50 at Piper Sandler
10/12/22 Piper Sandler
CMS proposal a positive for Med Tech sector, says Piper Sandler
08/12/22 Piper Sandler
Humacyte price target lowered to $3.50 from $4.00 at Piper Sandler
LNSR Lensar
$3.21 /

+0.02 (+0.63%)

04/19/22 BTIG
J&J results will be viewed favorably for MedTech group, says BTIG
VRAY ViewRay
$3.62 /

-0.265 (-6.82%)

VCEL Vericel
$29.42 /

-0.29 (-0.98%)

TMCI Treace Medical
$24.07 /

-0.66 (-2.67%)

SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

LNSR Lensar
$3.21 /

+0.02 (+0.63%)

IRTC iRhythm
$107.28 /

-8.07 (-7.00%)

HUMA Humacyte
$2.72 /

-0.11 (-3.89%)

ATRC AtriCure
$35.90 /

-1.72 (-4.57%)

  • 10
    Mar
  • 08
    Feb
TMCI Treace Medical
$24.07 /

-0.66 (-2.67%)

SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

VCEL Vericel
$29.42 /

-0.29 (-0.98%)

TMCI Treace Medical
$24.07 /

-0.66 (-2.67%)

SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

IRTC iRhythm
$107.28 /

-8.07 (-7.00%)

HUMA Humacyte
$2.72 /

-0.11 (-3.89%)

ATRC AtriCure
$35.90 /

-1.72 (-4.57%)

VRAY ViewRay
$3.62 /

-0.265 (-6.82%)

SIVB SVB Financial
$105.92 /

-0.04 (-0.04%)

Earnings
Vericel sees F Y23 revenue $180M-$188M, consensus $192.58M » 08:03
02/23/23
02/23
08:03
02/23/23
08:03
VCEL

Vericel

$28.46 /

-0.22 (-0.77%)

Sees FY23 gross margin…

Sees FY23 gross margin expected to be in the high-60% range. Adjusted EBITDA margin expected to be in the mid-teens % range.

ShowHide Related Items >><<
VCEL Vericel
$28.46 /

-0.22 (-0.77%)

VCEL Vericel
$28.46 /

-0.22 (-0.77%)

01/31/23 Truist
Vericel price target raised to $29 from $25 at Truist
01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
VCEL Vericel
$28.46 /

-0.22 (-0.77%)

VCEL Vericel
$28.46 /

-0.22 (-0.77%)

Earnings
Vericel reports Q4 EPS 12c, consensus 3c » 08:03
02/23/23
02/23
08:03
02/23/23
08:03
VCEL

Vericel

$28.46 /

-0.22 (-0.77%)

Reports Q4 revenue…

Reports Q4 revenue $52.7M, consensus $52.94M. "The Company delivered strong financial and business results to end the year as we generated record quarterly MACI and total revenue and another quarter of profitability," said Nick Colangelo, President and CEO of Vericel. "We also achieved significant development milestones for the Company with the approval of NexoBrid and an accelerated regulatory pathway for the MACI arthroscopic delivery program. Based on our current portfolio and anticipated new product launches, we believe that the Company is well-positioned to continue to deliver strong revenue and profit growth over the long term."

ShowHide Related Items >><<
VCEL Vericel
$28.46 /

-0.22 (-0.77%)

VCEL Vericel
$28.46 /

-0.22 (-0.77%)

01/31/23 Truist
Vericel price target raised to $29 from $25 at Truist
01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
VCEL Vericel
$28.46 /

-0.22 (-0.77%)

VCEL Vericel
$28.46 /

-0.22 (-0.77%)

Over a month ago
Recommendations
Vericel price target raised to $29 from $25 at Truist » 09:28
01/31/23
01/31
09:28
01/31/23
09:28
VCEL

Vericel

$27.02 /

-1.49 (-5.23%)

Truist analyst Samuel…

Truist analyst Samuel Brodovsky raised the firm's price target on Vericel to $29 from $25 but keeps a Hold rating on the shares as part of a broader research note previewing Q4 earnings in MedTech. The initial positive stock move in reaction to MACI Arthroscopic Program performance and the company's positive addressable market updates has faded more recently, and the firm is looking for increased visibility around revenue acceleration from NexoBrid, which could be a late 2023 catalyst for Vericel, the analyst tells investors in a research note.

ShowHide Related Items >><<
VCEL Vericel
$27.02 /

-1.49 (-5.23%)

VCEL Vericel
$27.02 /

-1.49 (-5.23%)

01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
VCEL Vericel
$27.02 /

-1.49 (-5.23%)

VCEL Vericel
$27.02 /

-1.49 (-5.23%)

On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:11
01/12/23
01/12
11:11
01/12/23
11:11
GRTX

Galera Therapeutics

$1.84 /

+ (+0.00%)

, CLLS

Cellectis

$3.84 /

+0.39 (+11.30%)

, ACHV

Achieve Life Sciences

$3.71 /

+0.01 (+0.27%)

, EIGR

Eiger BioPharmaceuticals

$1.35 /

+0.02 (+1.50%)

, VCEL

Vericel

$28.46 /

+0.84 (+3.04%)

These names in the…

ShowHide Related Items >><<
VCEL Vericel
$28.46 /

+0.84 (+3.04%)

GRTX Galera Therapeutics
$1.84 /

+ (+0.00%)

EIGR Eiger BioPharmaceuticals
$1.35 /

+0.02 (+1.50%)

CLLS Cellectis
$3.84 /

+0.39 (+11.30%)

ACHV Achieve Life Sciences
$3.71 /

+0.01 (+0.27%)

GRTX Galera Therapeutics
$1.84 /

+ (+0.00%)

11/28/22 Citi
Galera Therapeutics price target lowered to $18 from $20 at Citi
05/27/22 BofA
Galera Therapeutics downgraded to Underperform from Neutral at BofA
CLLS Cellectis
$3.84 /

+0.39 (+11.30%)

12/14/22 Citi
Cellectis price target lowered to $24 from $36 at Citi
08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
ACHV Achieve Life Sciences
$3.71 /

+0.01 (+0.27%)

11/16/22 Maxim
Achieve Life Sciences price target lowered to $8 from $21 at Maxim
11/15/22 Oppenheimer
Achieve Life Sciences price target lowered to $20 from $27 at Oppenheimer
04/27/22 Oppenheimer
Achieve Life Sciences price target raised to $27 from $23 at Oppenheimer
EIGR Eiger BioPharmaceuticals
$1.35 /

+0.02 (+1.50%)

01/03/23 BTIG
Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
12/12/22 BTIG
Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG
12/09/22 Baird
Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird
12/09/22 Citi
Eiger BioPharmaceuticals price target lowered to $4 from $23 at Citi
VCEL Vericel
$28.46 /

+0.84 (+3.04%)

01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
VCEL Vericel
$28.46 /

+0.84 (+3.04%)

GRTX Galera Therapeutics
$1.84 /

+ (+0.00%)

EIGR Eiger BioPharmaceuticals
$1.35 /

+0.02 (+1.50%)

CLLS Cellectis
$3.84 /

+0.39 (+11.30%)

ACHV Achieve Life Sciences
$3.71 /

+0.01 (+0.27%)

GRTX Galera Therapeutics
$1.84 /

+ (+0.00%)

EIGR Eiger BioPharmaceuticals
$1.35 /

+0.02 (+1.50%)

CLLS Cellectis
$3.84 /

+0.39 (+11.30%)

Hot Stocks
Vericel expects MACI arthroscopic commercial launch in 2024 » 07:58
01/10/23
01/10
07:58
01/10/23
07:58
VCEL

Vericel

$23.85 /

+0.13 (+0.55%)

Recent Business…

Recent Business Highlights and Updates: Following a Type C meeting with the FDA, the Company is planning to initiate a human factors validation study to support expanding the MACI label to include arthroscopic administration of MACI for the treatment of cartilage defects of the knee and now anticipates an accelerated potential commercial launch of arthroscopic MACI in 2024; Announced FDA approval of NexoBrid on December 28, 2022 for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns, with U.S. commercial availability expected in the second quarter of 2023; Expect to hold a pre-IND meeting with the FDA in the first half of 2023 to discuss the MACI development program for the treatment of cartilage defects in the ankle. "We made tremendous progress advancing our pipeline and expanding our business in 2022, highlighted by an accelerated regulatory pathway for the MACI arthroscopic delivery program and the recent approval of NexoBrid," said Nick Colangelo, President and CEO of Vericel. "We also had very strong MACI performance to close the year and we look forward to building on this momentum in 2023 across both of our franchises, as we expect accelerating total revenue growth this year and further acceleration in 2024 driven by a full year of NexoBrid on the market and the planned launch of arthroscopic MACI."

ShowHide Related Items >><<
VCEL Vericel
$23.85 /

+0.13 (+0.55%)

VCEL Vericel
$23.85 /

+0.13 (+0.55%)

01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
VCEL Vericel
$23.85 /

+0.13 (+0.55%)

Earnings
Vericel sees 2022 revenue $164M-$165M, consensus $164.62M » 07:57
01/10/23
01/10
07:57
01/10/23
07:57
VCEL

Vericel

$23.85 /

+0.13 (+0.55%)

Total net revenue for…

Total net revenue for full-year 2022 expected to be approximately $164 to $165 million; MACI net revenue for full-year 2022 expected to be approximately $132 million; Burn Care net revenue for full-year 2022 expected to be approximately $32.5 million; Fourth quarter MACI revenue growth expected to be approximately 24% versus prior year; Expect tenth straight quarter with positive adjusted EBITDA and Operating Cash Flow; As of December 31, 2022, the Company had approximately $140 million in cash and investments and no debt.

ShowHide Related Items >><<
VCEL Vericel
$23.85 /

+0.13 (+0.55%)

VCEL Vericel
$23.85 /

+0.13 (+0.55%)

01/03/23 H.C. Wainwright
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
VCEL Vericel
$23.85 /

+0.13 (+0.55%)

Recommendations
H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split » 11:24
01/03/23
01/03
11:24
01/03/23
11:24
MDWD

MediWound

$13.60 /

+0.15 (+1.12%)

, VCEL

Vericel

$25.02 /

-1.36 (-5.16%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth adjusted the firm's price target on MediWound (MDWD) to $23 from $5.50 and keeps a Buy rating on the shares to account for the reverse split of 1 for 7 shares that became effective on December 20 and the approval of NexoBrid by the FDA on December 29. While awaiting pricing details from Vericel (VCEL) management, Ramakanth currently assumes initial revenue of $6,500 per patient per burn treatment and assumes "meaningful" NexoBrid revenues to start from Q3 of 2023, the analyst noted.

ShowHide Related Items >><<
VCEL Vericel
$25.02 /

-1.36 (-5.16%)

MDWD MediWound
$13.60 /

+0.15 (+1.12%)

MDWD MediWound
$13.60 /

+0.15 (+1.12%)

12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
12/29/22 Oppenheimer
MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
12/22/22 Maxim
MediWound initiated with a Buy at Maxim
12/21/22 Oppenheimer
MediWound price target raised to $63 from $9 at Oppenheimer
VCEL Vericel
$25.02 /

-1.36 (-5.16%)

01/03/23 H.C. Wainwright
Vericel price target raised to $37 from $35 at H.C. Wainwright
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
11/09/22 BTIG
Vericel downgraded to Neutral from Buy at BTIG
VCEL Vericel
$25.02 /

-1.36 (-5.16%)

MDWD MediWound
$13.60 /

+0.15 (+1.12%)

  • 03
    Mar
MDWD MediWound
$13.60 /

+0.15 (+1.12%)

Recommendations
Vericel price target raised to $37 from $35 at H.C. Wainwright » 11:04
01/03/23
01/03
11:04
01/03/23
11:04
VCEL

Vericel

$25.03 /

-1.35 (-5.12%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Vericel to $37 from $35 and keeps a Buy rating on the shares following the FDA approval of NexoBrid. The drug received a wider label than expected as it can be applied up to two applications with an initial application that can cover an area of up to 15% of body surface area and a second application within 24 hours to cover an area of up to 20% of body surface area, Ramakanth tells investors in a research note. Based on the collaboration agreement with MediWound, Vericel is expected to pay a milestone payment of $7.5M in Q1, the analyst adds.

ShowHide Related Items >><<
VCEL Vericel
$25.03 /

-1.35 (-5.12%)

VCEL Vericel
$25.03 /

-1.35 (-5.12%)

12/30/22 TD Cowen
MediWound price target raised to $25 from $6 at Cowen
11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
11/09/22 BTIG
Vericel downgraded to Neutral from Buy at BTIG
11/09/22 Truist
Vericel downgraded to Hold from Buy at Truist
VCEL Vericel
$25.03 /

-1.35 (-5.12%)

Recommendations
MediWound price target raised to $25 from $6 at Cowen » 08:24
12/30/22
12/30
08:24
12/30/22
08:24
MDWD

MediWound

$13.37 /

+0.34 (+2.61%)

, VCEL

Vericel

$25.46 /

+1.21 (+4.99%)

Cowen analyst Joshua…

Cowen analyst Joshua Jennings raised the firm's price target on MediWound (MDWD) to $25 from $6 and keeps an Outperform rating on the shares after the FDA approved NexoBrid and triggered a $7.5M milestone from Vericel (VCEL). MediWound will benefit from high-single digit royalties on U.S. Nexobrid sales, also recently announced regulatory approvals in India and Japan and should secure EMA pediatric labeling in Q1, Jennings tells investors.

ShowHide Related Items >><<
VCEL Vericel
$25.46 /

+1.21 (+4.99%)

MDWD MediWound
$13.37 /

+0.34 (+2.61%)

MDWD MediWound
$13.37 /

+0.34 (+2.61%)

12/29/22 Oppenheimer
MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
12/22/22 Maxim
MediWound initiated with a Buy at Maxim
12/21/22 Oppenheimer
MediWound price target raised to $63 from $9 at Oppenheimer
11/16/22 H.C. Wainwright
MediWound price target lowered to $5.50 from $6 at H.C. Wainwright
VCEL Vericel
$25.46 /

+1.21 (+4.99%)

11/10/22 H.C. Wainwright
Vericel price target lowered to $35 from $53 at H.C. Wainwright
11/09/22 BTIG
Vericel downgraded to Neutral from Buy at BTIG
11/09/22 Truist
Vericel downgraded to Hold from Buy at Truist
10/13/22 Stephens
Vericel resumed with an Overweight at Stephens
VCEL Vericel
$25.46 /

+1.21 (+4.99%)

MDWD MediWound
$13.37 /

+0.34 (+2.61%)

  • 03
    Mar
MDWD MediWound
$13.37 /

+0.34 (+2.61%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.